| 朱 琳,杨 柳,卞 军,李 蕊,程晓丽,辛毅娟.血清HE4、B7H4表达水平及全身免疫炎症指数与卵巢癌患者临床病理特征及肿瘤转移的关系[J].现代生物医学进展英文版,2024,(18):3460-3464. |
| 血清HE4、B7H4表达水平及全身免疫炎症指数与卵巢癌患者临床病理特征及肿瘤转移的关系 |
| The Relationship between Serum HE4 and B7H4 Expression Levels, Systemic Immune Inflammation Index, Clinical Pathological Characteristics, and Tumor Metastasis in Ovarian Cancer Patients |
| Received:February 06, 2024 Revised:February 28, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.18.011 |
| 中文关键词: 附睾蛋白4 B7同源体4 全身免疫炎症指数 卵巢癌 |
| 英文关键词: Epididymal protein 4 B7 homolog 4 Systemic immune inflammation index Ovarian cancer |
| 基金项目:陕西省自然科学基金项目（2023-JC-YB-807） |
|
| Hits: 43 |
| Download times: 27 |
| 中文摘要: |
| 摘要 目的：探讨血清附睾蛋白4（HE4）、B7同源体4（B7H4）表达水平及全身免疫炎症指数（SII）与卵巢癌患者临床病理特征及肿瘤转移的关系。方法：选取我院2017年1月到2020年1月收治的80例卵巢癌患者，将其分为恶性组，另选取同期80例良性卵巢病变患者分为良性组，80名健康者作为对照组。对比三组受检者血清HE4、B7H4及SII表达水平。分析不同临床病理特征及肿瘤转移患者HE4、B7H4及SII表达水平，并采用Spearman相关性分析HE4、B7H4及SII与卵巢癌临床病理特征及肿瘤转移的相关性。并随访3年，记录总生存时间，分析HE4、B7H4及SII与卵巢癌生存期的关系。结果：三组患者HE4、B7H4及SII表达水平对比差异显著，恶性组明显高于良性组与对照组（P＜0.05）；不同年龄、组织学类型卵巢癌患者HE4、B7H4及SII表达水平对比无明显差异（P＞0.05），不同FIGO分期、淋巴结转移、远处转移、肿瘤分化程度患者HE4、B7H4及SII表达水平对比差异显著（P＜0.05）；Spearman相关分析结果表明，HE4、B7H4及SII与卵巢癌组织学类型无明显相关性，与FIGO分期、淋巴结转移、远处转移及肿瘤分化程度呈正相关（P＜0.05）；所有患者进行4年随访，HE4高水平患者中位总生存时间为23.53（6.42~42.13）个月个月明显低于低水平患者中位总生存时间32.54（14.53~42.13）个月。B7H4高水平患者中位总生存时间为21.32（6.42~42.13）个月明显低于低水平患者中位总生存时间31.32（14.63~42.13）个月。SII高水平患者中位总生存时间为20.36（6.42~42.13）个月明显低于低水平患者中位总生存时间34.68（13.56~42.13）个月（P＜0.05）。结论：血清HE4、B7H4、SII表达与卵巢癌临床分期、淋巴结转移、远处转移及肿瘤分化程度相关，且三者高表达可能意味着患者预后不良。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the expression levels of serum Epididymal protein 4 (HE4) and B7 homolog 4 (B7H4), as well as the relationship between systemic immune inflammation index (SII) and clinical pathological characteristics and tumor metastasis in ovarian cancer patients. Methods: 80 ovarian cancer patients admitted to our hospital from January 2017 to January 2020 were divided into malignant group, 80 patients with benign ovarian lesions in the same period were divided into benign group, and 80 healthy patients were selected as the control group. The serum expression levels of HE4, B7H4 and SII were compared in the three groups. The expression levels of HE4, B7H4 and SII in patients with tumor metastasis, and Spearman correlation between HE4, B7H4 and SII and the clinicopathological features of ovarian cancer and tumor metastasis. And followed up for 3 years, record the overall survival time, and analyze the relationship between HE4, B7H4 and SII and ovarian cancer survival. Results: There were differences in the expression levels of HE4, B7H4, and SII among the three groups of patients. The malignant group was significantly higher than the benign group and the control group(P<0.05); There was no difference in the expression levels of HE4, B7H4, and SII among ovarian cancer patients of different ages and histological types(P>0.05). However, there were differences in the expression levels of HE4, B7H4, and SII among patients with different FIGO stages, lymph node metastasis, distant metastasis, and tumor differentiation degree(P<0.05); The Spearman correlation analysis results showed that HE4, B7H4, and SII were not significantly correlated with the histological type of ovarian cancer, but were positively correlated with FIGO staging, lymph node metastasis, distant metastasis, and tumor differentiation degree(P<0.05); All patients were followed up for 4 years, and the median overall survival time of patients with high HE4 levels was 23.53 (6.42-42.13) months, which was lower than that of patients with low HE4 levels, which was 32.54 (14.53-42.13) months. The median overall survival time of B7H4 high-level patients was 21.32 (6.42-42.13) months, which was lower than that of low-level patients at 31.32 (14.63-42.13) months. The median overall survival time of patients with high-level SII was 20.36 (6.42-42.13) months, which was lower than that of patients with low-level SII at 34.68 (13.56-42.13) months(P<0.05). Conclusion: Serum expression of HE4, B7H4 and SII are correlated with clinical stage of ovarian cancer, lymph node metastasis, distant metastasis and degree of tumor differentiation, and high expression of the three may mean poor prognosis of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
